Kingston, Jamaica (McKoy’s News) – Dr Henry Lowe Makes FDA Breakthrough: A drug developed from cannabis by Jamaican scientist Dr. Henry Lowe to treat acute myeloid leukaemia has been granted orphan-drug designation by the United States Food and Drug Administration (FDA).
Dr. Lowe pointed out that the FDA designation could see the drug, which has the trade name Cresorol, being placed on the market within three years, with estimated annual minimum sales of more than US$250 million in the US market alone.
“As far as I am aware, this is the first time that anyone from a developing country like Jamaica has been able to achieve this feat of starting from the isolation of a bioactive molecule and working it up to provide a new drug from scratch, which is recognised by the FDA.”
Lowe, known globally for using the properties of Jamaican plants, particularly ball moss and cannabis, in his cancer research, was notified of the approval late last month.
CEO Utimatexperience Radio